Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparative efficacy of once-a-day extended-release methylphenidate, two-times-daily immediate-release methylphenidate, and placebo in a laboratory school setting.
Döpfner M, Gerber WD, Banaschewski T, Breuer D, Freisleder FJ, Gerber-von Müller G, Günter M, Hässler F, Ose C, Rothenberger A, Schmeck K, Sinzig J, Stadler C, Uebel H, Lehmkuhl G. Döpfner M, et al. Among authors: freisleder fj. Eur Child Adolesc Psychiatry. 2004;13 Suppl 1:I93-101. doi: 10.1007/s00787-004-1009-3. Eur Child Adolesc Psychiatry. 2004. PMID: 15322960 Clinical Trial.
What can actigraphy add to the concept of labschool design in clinical trials?
Uebel H, Albrecht B, Kirov R, Heise A, Döpfner M, Freisleder FJ, Gerber WD, Günter M, Hässler F, Ose C, Poustka F, Fischer R, Banaschewski T, Rothenberger A. Uebel H, et al. Among authors: freisleder fj. Curr Pharm Des. 2010;16(22):2434-42. doi: 10.2174/138161210791959845. Curr Pharm Des. 2010. PMID: 20513227 Clinical Trial.
Effectiveness and tolerability of olanzapine in the treatment of adolescents with schizophrenia and related psychotic disorders: results from a large, prospective, open-label study.
Dittmann RW, Meyer E, Freisleder FJ, Remschmidt H, Mehler-Wex C, Junghanss J, Hagenah U, Schulte-Markwort M, Poustka F, Schmidt MH, Schulz E, Mästele A, Wehmeier PM. Dittmann RW, et al. Among authors: freisleder fj. J Child Adolesc Psychopharmacol. 2008 Feb;18(1):54-69. doi: 10.1089/cap.2006.0137. J Child Adolesc Psychopharmacol. 2008. PMID: 18294089
Olanzapine in male and female adolescent patients with schizophrenia and related disorders: minor sex differences in outcomes.
Dittmann RW, Meyer E, Freisleder FJ, Remschmidt H, Mehler-Wex C, Junghanss J, Hagenah U, Schulte-Markwort M, Poustka F, Schulz E, Kluge M, Mästele A, Wehmeier PM, Schmidt MH. Dittmann RW, et al. Among authors: freisleder fj. J Clin Psychopharmacol. 2010 Jun;30(3):328-31. doi: 10.1097/JCP.0b013e3181dc6935. J Clin Psychopharmacol. 2010. PMID: 20473072 Clinical Trial. No abstract available.
Polygenic Risk: Predicting Depression Outcomes in Clinical and Epidemiological Cohorts of Youths.
Halldorsdottir T, Piechaczek C, Soares de Matos AP, Czamara D, Pehl V, Wagenbuechler P, Feldmann L, Quickenstedt-Reinhardt P, Allgaier AK, Freisleder FJ, Greimel E, Kvist T, Lahti J, Räikkönen K, Rex-Haffner M, Arnarson EÖ, Craighead WE, Schulte-Körne G, Binder EB. Halldorsdottir T, et al. Among authors: freisleder fj. Am J Psychiatry. 2019 Aug 1;176(8):615-625. doi: 10.1176/appi.ajp.2019.18091014. Epub 2019 Apr 5. Am J Psychiatry. 2019. PMID: 30947532
21 results